Cargando…

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice

Targeting tumor-driven angiogenesis is an effective strategy in the management of metastatic colorectal cancer (mCRC); however, the choice of second-line therapy is complicated by the availability of several drugs, the occurrence of resistance and the lack of validated prognostic and predictive biom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Eleonora, Cascinu, Stefano, Scartozzi, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141840/ https://www.ncbi.nlm.nih.gov/pubmed/34041019 http://dx.doi.org/10.3389/fonc.2021.637823

Ejemplares similares

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion
por: Cascinu, Stefano, et al.
Publicado: (2022)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
por: Mariani, Stefano, et al.
Publicado: (2022)

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
por: Maccaroni, Elena, et al.
Publicado: (2015)

New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression
por: Ziranu, Pina, et al.
Publicado: (2023)

Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
por: Goel, Gaurav, et al.
Publicado: (2015)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy
por: Schiffmann, Lars M., et al.
Publicado: (2022)

Expert opinions on immunotherapy for patients with colorectal cancer
por: Wang, Feng, et al.
Publicado: (2020)

Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
por: Lin, Dengqiang, et al.
Publicado: (2023)

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2012)

Mesothelial Inclusions in Pelvic Lymph Nodes Initially Diagnosed as Metastatic Prostate Cancer; the Utility of Second Opinions and Genomic Testing in the Setting of Unexpected Results
por: Joudi, Fadi, et al.
Publicado: (2016)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Experts Opinion
por: Goldberg, Ivan, et al.
Publicado: (2012)

Expert Opinion
Publicado: (1920)

The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
por: Gil, Lucia, et al.
Publicado: (2022)

Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
por: D'Aniello, Carmine, et al.
Publicado: (2019)

Personalized Human Papillomavirus Vaccination for Persistence of Immunity for Cervical Cancer Prevention: A Critical Review With Experts' Opinions
por: Chambuso, Ramadhani Salum, et al.
Publicado: (2020)

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
por: Xue, Wen-Hui, et al.
Publicado: (2023)

Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study
por: Archwamety, Anita, et al.
Publicado: (2022)

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
por: Nakatsumi, Hiroshi, et al.
Publicado: (2022)

Evaluation of (18)F-FMISO PET and (18)F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy
por: Lee, Sze Ting, et al.
Publicado: (2021)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

More Expert Opinion
Publicado: (1920)

Management of B-cell lineage acute lymphoblastic leukemia: expert opinion from an Indian panel via Delphi consensus method
por: Mathews, Vikram, et al.
Publicado: (2023)

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis
por: Giampieri, Riccardo, et al.
Publicado: (2017)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Second-Line Systemic Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
por: Yoon, Hyun Sik, et al.
Publicado: (2019)

The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy
por: Zhao, Xiao-Han, et al.
Publicado: (2023)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Impact of Second Opinions in Breast Cancer Diagnostics and Treatment: A Retrospective Analysis
por: Heeg, E., et al.
Publicado: (2019)

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines
por: Davidson, Brittany Anne, et al.
Publicado: (2014)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center
por: Rupani, Asha, et al.
Publicado: (2020)

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hqo8juclctp8ovmv4pbr5q6i76